Studies on Nucleic Acid Antagonists. II. Structure-Activity Relationship in 5-Phenylazopyrimidines.

  • 田中 邦喜
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 大村 栄之助
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 川島 実
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 渡辺 順明
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 横谷 肇
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 伊藤 宝務
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 杉野 幸夫
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 石館 基
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 荒木 豊成
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 荒蒔 義知
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.
  • 梶原 彊
    Research Laboratories, Takeda Pharmaceutical Industries, Ltd.

この論文をさがす

抄録

Among the 5-phenylazopyrimidine derivatives reported in the preceding paper, some members showed a remarkable inhibitory effect upon the growth of Lactobacillus casei, Tetrahymena geleii, as well as chick embyro fibroblast. Others which were only slightly effective, had anti-tumor activity against Yoshida sarcoma and Ehrlich carcinoma. As a result of study on the structure-activity relationships in these compounds, it was found that 2,4,6-triamino-5-phenylazopyrimidines, in which the para-position of the benzene ring of the 5-phenylazogroup was substituted with sulfonic acid, sulfonamide, carboxylic acid, or phosphonic acid group, were effective upon several transplantable tumors in experimental animals and their anti-tumor activity increased by a combined administration with other nucleic acid antagonists such as 6-mercaptopurine.

収録刊行物

詳細情報 詳細情報について

  • CRID
    1573105977282838784
  • NII論文ID
    110003618099
  • NII書誌ID
    AA00602100
  • ISSN
    00092363
  • 本文言語コード
    en
  • データソース種別
    • CiNii Articles

問題の指摘

ページトップへ